To investigate the pathologic response rates and survival associated with 3 versus 4 cycles of cisplatin-based NAC in patients with cT2-4N0M0 MIBC.
In this cohort study we analyzed clinical data of 828 patients treated with NAC and RC between 2000 and 2020.